Skip to main content

Advertisement

Table 3 Immunologic responses to the pneumococcal and influenza vaccines at Day 28 post-vaccination

From: Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

  Pneumococcal vaccine (n = 113) Influenza vaccine (n = 186)
Primary definition
 Patients without protective antibody levels at baselinea   
  n/N (%) 34/46 (73.9) 73/119 (61.3)
  95 % CI 61.2, 86.6 52.6, 70.1
 Patients with protective antibody levels at baseline   
  n/N (%) 28/66 (42.4) 18/65 (27.7)
  95 % CI 30.5, 54.3 16.8, 38.6
 Total   
  n/N (%) 62/112 (55.4) 91/184 (49.5)
  95 % CI 46.2, 64.6 42.2, 56.7
Conservative definition
 Patients without protective antibody levels at baselinea   
  n/N (%) 16/46 (34.8) N/A
  95 % CI 21.0, 48.5
 Patients with protective antibody levels at baseline   
  n/N (%) 8/65 (12.3) N/A
  95 % CI 4.3, 20.3
 Total   
  n/N (%) 24/111 (21.6) N/A
  95 % CI 14.0, 29.3
  1. CI confidence interval, N/A not applicable
  2. aPrimary endpoint. Patients with >42 days between the pre- and post-vaccination sample dates were excluded from the analysis. One patient from the pneumococcal study had >42 days between pre- and post-vaccination samples (57 days) and did not have protective antibody levels at baseline; the patient did not achieve an immunologic response post-vaccination. Two patients from the influenza study had >42 days between pre- and post-vaccination sample (46 days: patient did not have protective antibodies at baseline and did not achieve an immunologic response post-vaccination; 43 days: patient did not have protective antibodies at baseline and achieved immunologic response post-vaccination)